BHVN
BHVN clinical trials: Biohaven Ltd.
Every trial on ClinicalTrials.gov where Biohaven Ltd. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 43
- Trials linked
- 35
- As lead sponsor
- 8
- As collaborator
- 2
- Primary completions as lead sponsor, next 90 days
BHVN on the catalyst calendar · BHVN registry changes
- Primary completion Jan 2028Sponsor estimatePhase 3NCT07661056Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' DiseaseBiohaven Therapeutics Ltd. · Graves DiseaseRecruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2027Sponsor estimatePhase 1NCT07262268A Phase 1b Study of BHV-7000 in Participants With Inherited ErythromelalgiaBiohaven Therapeutics Ltd. · Familial ErythromelalgiaActive, not recruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 6, 2024ActualNo phase registeredNCT06529146Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History ControlBiohaven Therapeutics Ltd. · Spinocerebellar AtaxiasCompletedBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 18, 2022ActualPhase 3NCT03701399Troriluzole in Adult Participants With Spinocerebellar AtaxiaBiohaven Pharmaceuticals, Inc. · Spinocerebellar AtaxiasCompletedBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 27, 2025ActualPhase 3NCT04641143Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive DisorderBiohaven Pharmaceuticals, Inc. · Obsessive-Compulsive DisorderCompletedBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 2/Phase 3NCT07901244An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' DiseaseBiohaven Therapeutics Ltd. · Graves' DiseaseNot yet recruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 2/Phase 3NCT06976268A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's DiseaseBiohaven Therapeutics Ltd. · Parkinson DiseaseRecruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 18, 2026ActualPhase 2NCT06423781Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)Biohaven Therapeutics Ltd. · Major Depressive DisorderCompletedBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 7, 2025ActualPhase 2NCT06419608Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionBiohaven Therapeutics Ltd. · Major Depressive DisorderCompletedBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2/Phase 3NCT06132893A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyBiohaven Therapeutics Ltd. · Focal EpilepsyActive, not recruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimatePhase 1/Phase 2NCT06384807A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid TumorsBiohaven Therapeutics Ltd. · Solid TumorRecruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2026Sponsor estimatePhase 2/Phase 3NCT06309966Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyBiohaven Therapeutics Ltd. · Focal EpilepsyActive, not recruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 1NCT06980649Study of BHV-1300 in Graves' DiseaseBiohaven Therapeutics Ltd. · Graves DiseaseRecruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 1NCT06874335A Phase 1 Study of BHV-1530 in Advanced Solid TumorsBiohaven Therapeutics Ltd. · Solid TumorRecruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd. · IgA NephropathyRecruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 3NCT07642050A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA NephropathyBiohaven Therapeutics Ltd. · IgA NephropathyNot yet recruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 25, 2024ActualPhase 3NCT05337553A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular AtrophyBiohaven Pharmaceuticals, Inc. · Spinal Muscular AtrophyActive, not recruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06443463Long-term Safety and Tolerability of BHV-7000Biohaven Therapeutics Ltd. · Focal EpilepsyEnrolling by invitationBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2025ActualPhase 3NCT04693351A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive DisorderBiohaven Pharmaceuticals, Inc. · Obsessive-Compulsive DisorderCompletedBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 12, 2026ActualPhase 2/Phase 3NCT06425159A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic SeizuresBiohaven Therapeutics Ltd. · Generalized EpilepsyTerminatedBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2026Sponsor estimatePhase 2NCT07281495Taldefgrobep Alfa in Adults With Overweight and ObesityBiohaven Therapeutics Ltd. · ObesityActive, not recruitingBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 24, 2025ActualPhase 2NCT06603623Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of MigraineBiohaven Therapeutics Ltd. · MigraineCompletedBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 13, 2026ActualPhase 3NCT04708834Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive DisorderBiohaven Pharmaceuticals, Inc. · Obsessive Compulsive DisorderTerminatedBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06034886Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)Biohaven Pharmaceuticals, Inc. · SCAAvailableBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2, 2020ActualPhase 2/Phase 3NCT03299166Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive DisorderBiohaven Pharmaceuticals, Inc. · Obsessive-Compulsive DisorderCompletedBHVNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 18 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner